Immuron (NASDAQ:IMRN) Stock Falls 2.5% – Here’s Why

Immuron (NASDAQ:IMRN)’s share price fell 2.5% on Friday. The company traded as low as $1.16 and last traded at $1.16. 43,882 shares were traded during mid-day trading, a decline of 99% from the average session volume of 6,531,659 shares. The stock had previously closed at $1.19.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Immuron in a research report on Monday. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has an average rating of “Sell”.

Immuron Stock Down 2.5%

The company’s 50 day simple moving average is $1.21 and its 200 day simple moving average is $1.06.

Immuron (NASDAQ:IMRN) last issued its earnings results on Friday, August 14th. The company reported ($0.08) earnings per share (EPS) for the quarter. The firm had revenue of $1.27 million for the quarter.

Immuron Company Profile

Immuron Limited (NASDAQ: IMRN) is a biopharmaceutical company focused on developing and commercializing orally delivered therapeutics based on highly specific antibodies derived from hyperimmune bovine colostrum. Its approach is designed to target pathogens and disease-related factors within the gastrointestinal tract without requiring systemic absorption.

The company’s leading commercial product is Travelan, an oral antibody-based product intended to help prevent travelers’ diarrhea caused by enterotoxigenic Escherichia coli (ETEC).